Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance.

Antimicrobial agents and chemotherapy - 1 Dec 2004

Johnston Elizabeth, Winters Mark A, Rhee Soo-Yon, Merigan Thomas C, Schiffer Celia A, Shafer Robert W

Abstract excerpt

We observed a previously uncharacterized mutation in the protease substrate cleft, L23I, in 31 of 4,303 persons undergoing human immunodeficiency virus type 1 genotypic resistance testing. In combination with V82I, L23I was associated with a sevenfold reduction in nelfinavir susceptibility and a decrease in replication capacity. In combination with other drug resistance mutations, L23I was associated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to HIV-1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Models, Molecular

Share to Oligopeptides

Share to Protein Conformation

Source

Open in PubMed Open full text

Identifiers

PMID: 15561868
DOI: 10.1128/AAC.48.12.4864-4868.2004
PMCID: PMC529213

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance.PMID 15561868Read ↗

HIV protease mutations leading to reduced inhibitor susceptibility.Semantic proximity Read ↗

The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.Semantic proximity Read ↗

Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.Semantic proximity Read ↗

Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors.Semantic proximity Read ↗

A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.Semantic proximity Read ↗

Molecular basis for reduced cleavage activity and drug resistance in D30N HIV-1 protease.Semantic proximity Read ↗

Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases.Semantic proximity Read ↗

Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors.Semantic proximity Read ↗

Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.Semantic proximity Read ↗

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.Semantic proximity Read ↗

Ninety-Nine Is Not Enough: Molecular Characterization of Inhibitor-Resistant Human Immunodeficiency Virus Type 1 Protease Mutants with Insertions in the Flap RegionSemantic proximity Read ↗

Molecular Basis for Reduced Cleavage Activity and Drug Resistance in D30N HIV-1 proteaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.